Eli Lilly expands weight-loss drug market and enforcement

Eli Lilly is simultaneously expanding its weight-loss drug portfolio internationally through regulatory approvals while aggressively pursuing legal action against black market sellers of its unapproved experimental drug retatrutide. The company has won U.K. approval for Foundayo and filed lawsuits against multiple U.S.-based entities illegally selling unauthorized versions of drugs still in clinical trials.

This is a long-running storyline that has developed over 6 days. The homepage highlights its most recent activity, so the outlet count there reflects the latest wave. The totals above cover the full run.